Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... [Yahoo! Finance]
Chimerix, Inc. (CMRX)
Last chimerix, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.chimerix.com/investor-relations
Company Research
Source: Yahoo! Finance
General and Administrative Expenses: Decreased to $5.2 million for Q3 2024 from $9.3 million in Q3 2023. Cash and Cash Equivalents: Over $152 million at the end of Q3 2024. Cash Runway: Extending into Q4 2026. Warning! GuruFocus has detected 6 Warning Signs with CMRX. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Chimerix Inc ( NASDAQ:CMRX ) is nearing complete enrollment of its phase one dose escalation studies for ONC206, indicating progress in its pipeline. The phase three action study of dordaviprone is active in 15 countries, with the first interim data readout potentially less than a year away. The independent Data Monitoring Committee recommended the continuation of the action study without changes, highlighting the safety profile of dordaviprone. Chimerix Inc ( NASDAQ:CMRX ) is preparing for potential commercialization of dordaviprone, forecasting a global market opportunit
Show less
Read more
Impact Snapshot
Event Time:
CMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMRX alerts
High impacting Chimerix, Inc. news events
Weekly update
A roundup of the hottest topics
CMRX
News
- Chimerix, Inc. (NASDAQ: CMRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.MarketBeat
- Chimerix, Inc. (NASDAQ: CMRX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.MarketBeat
- Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? [Yahoo! Finance]Yahoo! Finance
- Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End [Yahoo! Finance]Yahoo! Finance
- Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndGlobeNewswire
CMRX
Earnings
- 11/7/24 - Miss
CMRX
Sec Filings
- 12/10/24 - Form 8-K
- 11/14/24 - Form 8-K
- 11/7/24 - Form 10-Q
- CMRX's page on the SEC website